Acoramidis - ATTRUBY tablets

The official label describes early serum-creatinine increases and indexed-eGFR decreases that generally stabilized and reversed after discontinuation. The PK section reports no clinically significant difference based on renal impairment, but the selected sentence does not define numerical stages or a dialysis schedule.

Do not equate this observation with proof of unchanged filtration in every patient or borrow another medicine's creatinine-transport explanation. A new or progressive renal abnormality still needs clinical assessment.

Serum creatinine can rise and indexed eGFR can fall early after initiation, then stabilize. In the trial, these changes were seen within four weeks and were reversible after stopping therapy. The selected pharmacokinetic statement reports no clinically significant exposure difference by renal impairment, without assigning numerical renal-stage boundaries.

This finding does not establish a dialysis regimen or a universal acceptable creatinine rise. Assess a worsening renal trend in its clinical context; the observed biomarker pattern does not exclude intercurrent kidney injury.